Compare Aurobindo Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs BIOCON - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA BIOCON AUROBINDO PHARMA/
BIOCON
 
P/E (TTM) x 11.0 19.3 56.9% View Chart
P/BV x 2.4 3.0 79.8% View Chart
Dividend Yield % 0.5 0.4 135.5%  

Financials

 AUROBINDO PHARMA   BIOCON
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
BIOCON
Mar-18
AUROBINDO PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs8091,188 68.1%   
Low Rs504305 165.2%   
Sales per share (Unadj.) Rs281.168.7 409.0%  
Earnings per share (Unadj.) Rs41.47.6 547.6%  
Cash flow per share (Unadj.) Rs50.914.0 364.2%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.40.1 284.3%  
Book value per share (Unadj.) Rs199.486.3 230.9%  
Shares outstanding (eoy) m585.88600.00 97.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.310.9 21.5%   
Avg P/E ratio x15.998.9 16.1%  
P/CF ratio (eoy) x12.953.4 24.1%  
Price / Book Value ratio x3.38.6 38.1%  
Dividend payout %6.013.2 45.7%   
Avg Mkt Cap Rs m384,630447,900 85.9%   
No. of employees `00017.36.1 281.9%   
Total wages/salary Rs m21,3089,311 228.9%   
Avg. sales/employee Rs Th9,500.76,705.8 141.7%   
Avg. wages/employee Rs Th1,229.41,514.2 81.2%   
Avg. net profit/employee Rs Th1,397.9736.9 189.7%   
INCOME DATA
Net Sales Rs m164,66641,234 399.3%  
Other income Rs m1,0202,062 49.5%   
Total revenues Rs m165,68643,296 382.7%   
Gross profit Rs m37,7188,291 454.9%  
Depreciation Rs m5,5803,851 144.9%   
Interest Rs m777615 126.4%   
Profit before tax Rs m32,3805,887 550.0%   
Minority Interest Rs m31213 14.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,569 521.5%   
Profit after tax Rs m24,2294,531 534.7%  
Gross profit margin %22.920.1 113.9%  
Effective tax rate %25.326.7 94.8%   
Net profit margin %14.711.0 133.9%  
BALANCE SHEET DATA
Current assets Rs m121,87841,486 293.8%   
Current liabilities Rs m86,80621,413 405.4%   
Net working cap to sales %21.348.7 43.8%  
Current ratio x1.41.9 72.5%  
Inventory Days Days13064 203.0%  
Debtors Days Days6894 72.6%  
Net fixed assets Rs m81,03750,661 160.0%   
Share capital Rs m5863,000 19.5%   
"Free" reserves Rs m116,21848,808 238.1%   
Net worth Rs m116,80451,808 225.5%   
Long term debt Rs m4,51217,898 25.2%   
Total assets Rs m211,05299,897 211.3%  
Interest coverage x42.710.6 403.5%   
Debt to equity ratio x00.3 11.2%  
Sales to assets ratio x0.80.4 189.0%   
Return on assets %11.85.2 230.0%  
Return on equity %20.78.7 237.2%  
Return on capital %27.49.6 284.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72712,058 669.5%   
Fx outflow Rs m34,7007,348 472.2%   
Net fx Rs m46,0274,710 977.2%   
CASH FLOW
From Operations Rs m19,5486,621 295.2%  
From Investments Rs m-19,570-6,840 286.1%  
From Financial Activity Rs m8,642-2,397 -360.5%  
Net Cashflow Rs m8,922-2,612 -341.6%  

Share Holding

Indian Promoters % 54.1 40.4 133.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.0 8.4 94.6%  
FIIs % 27.7 10.7 258.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 19.9 51.3%  
Shareholders   69,601 109,995 63.3%  
Pledged promoter(s) holding % 8.6 0.0 21,400.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   PROCTER & GAMBLE HEALTH  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 95 Points Higher; Automobile and IT Stocks Witness Buying(Closing)

Indian share markets traded rangebound throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the automobile sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 23, 2019 03:37 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - TORRENT PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS